Can CVS Overcome the Drug Poised to "Break the Country?"

Consider the following quotes:

"What they have done with this particular drug will break the country."

"We expect the impact to be minimal for this year."

These two quotes, the first from Express Scripts'  (NASDAQ: ESRX  ) chief medical officer Steven Miller, the second from John Roberts, president of CVS Caremark 's (NYSE: CVS  ) Pharmacy Services division, are about the same drug: Gilead's (NASDAQ: GILD  ) Sovaldi. CVS is clearly confident in its plan to handle the increased hepatitis C spending caused by Sovaldi's excellent cure rate and $84,000 per patient price tag -- Express Scripts is not.

CVS' confidence doesn't just contrast with Express Scripts, either. UnitedHealth Group (NYSE: UNH  )  , the largest insurer in the United States, also had difficulty handling demand, which was "a multiple" of what management had expected.

CVS appears to have controlled well for the expense, and additional projects like the Minute Clinic concept appear poised to drive further growth at this impressive company. 

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson discuss CVS' potentially strong future and how the company continues to embarrass its competitors.

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2961459, ~/Articles/ArticleHandler.aspx, 9/5/2015 6:42:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:01 PM
CVS $100.12 Down -1.47 -1.45%
CVS Health CAPS Rating: ****
ESRX $83.10 Down -0.76 -0.91%
Express Scripts CAPS Rating: *****
GILD $102.06 Up +0.15 +0.15%
Gilead Sciences CAPS Rating: *****
UNH $112.36 Down -1.63 -1.43%
UnitedHealth Group CAPS Rating: *****